证券代码：002082 证券简称：万邦德 投资者关 系活动类 别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 ☑ 电话会议 □其他：（请文字说明其他活动内容） 参与单位 名称及人 员姓名 华鑫证券 吴景欢 中原证券 李琳琳 时间 2025 年 9 月 18 日 15:30-16:30 地点 公司会议室 公司接待 人员姓名 副总经理、董秘：柳建朋 医药研究院院长：赵冠甲 证券事务代表：陈黎莎 投资者关 系活动主 要内容介 绍 一、公司介绍环节 公司医药研究院院长主要围绕公司创新药管线进行介绍。 二、互动交流环节 1、请介绍下阿尔茨海默病 II/III 期临床试验的相关情况？公司石 杉碱甲的特点是什么？ 答：公司开展的阿尔茨海默病 II/III 期临床研究，采用多中心、 随机、双盲双模拟的设计，同时设有安慰剂和阳性药双对照，全面 地评价疗效与安全性。作为国内规模最大的阿尔茨海默病关键注册 临床研究，其方案设计科学且完整。不但设计了 ADAS-Cog 和 ADCS-ADL 双终点，以全面反映患者的认知功能和日常生活能力，还 将研究药物对疾病进程的影响。同时，也将通过 ...

Core Viewpoint - The company reported a 12.66% year-on-year increase in net profit attributable to shareholders, reaching 55.44 million yuan, and achieved a positive operating cash flow of 120 million yuan in 2024, highlighting significant improvements in its financial performance [1] Financial Performance - The company's net profit attributable to shareholders increased by 12.66% year-on-year, amounting to 55.44 million yuan [1] - Operating cash flow turned positive, achieving 120 million yuan in 2024 [1] - The medical device segment significantly reduced losses by 42.49%, while the South African business turned profitable with a year-on-year net profit growth of 211.68% [1][2] Business Segments - The South African business segment achieved profitability after years of effort, marking a key highlight in the company's operational performance [2] - The company has established a strong presence in the medical device sector, with multiple orthopedic implant products certified by the FDA and CE, and a robust pipeline of new products under development [2] - The company has been focusing on the South African market for medical device distribution and maintenance services, building a stable customer base and market reputation [2][3] Innovation and R&D - The company has made significant breakthroughs in new drug development, particularly in the field of neurological drugs, with a focus on the development of the huperzine A series and methionine preparations [1][4] - As of the end of the reporting period, the company had seven new drug pipelines under research, with five of them being dual-filed in China and the U.S., indicating high-quality pipeline development [4] - The company has received FDA clinical trial approvals for WP107 and WP103, both of which are based on huperzine A, a potent cholinesterase inhibitor [4][6] Future Outlook - The company plans to enhance its international strategy by increasing the export of domestic medical devices, aiming to create a new profit contribution point [3] - The company is committed to advancing its R&D capabilities by leveraging artificial intelligence in drug development and production quality control [7] - The company aims to become a leading enterprise in the pharmaceutical and health industry through technological innovation and collaboration with academic institutions [7]